Peroxisome Proliferator–Activated Receptor-γ Activation With Pioglitazone Improves Endothelium-Dependent Dilation in Nondiabetic Patients With Major Cardiovascular Risk Factors
- 14 February 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 113 (6), 867-875
- https://doi.org/10.1161/circulationaha.105.549618
Abstract
Background— Patients with cardiovascular risk factors have endothelial dysfunction, a key element in the pathogenesis of atherosclerosis. The thiazolidinediones have been shown to exert multiple antiatherosclerotic actions in diabetic patients. This study tested the hypothesis that pioglitazone improves endothelial function in nondiabetic patients with major risk factors. Methods and Results— The study had a randomized, double-blind, placebo-controlled, crossover design. Eighty patients with either hypertension or hypercholesterolemia were enrolled. Insulin sensitivity was assessed by the Quantitative Insulin Sensitivity Check Index (QUICKI), and patients were further classified as insulin sensitive or insulin resistant. In each treatment phase, patients received either pioglitazone 45 mg daily or placebo for 8 weeks. Endothelial function and laboratory tests were performed at the end of each 8-week period. Treatment with pioglitazone significantly lowered plasma insulin (−22.9%; P P P P =0.003), free fatty acids (−14%; P =0.005), and C-reactive protein (−28.6%; P =0.001). Pioglitazone treatment significantly improved endothelium-dependent dilation to bradykinin ( P =0.01) without affecting the response to sodium nitroprusside ( P =0.31). In multivariable analysis, only changes in total cholesterol were predictors of improved endothelial reactivity with pioglitazone. Conclusions— In nondiabetic patients with cardiovascular risk factors, pioglitazone treatment enhances insulin sensitivity, decreases C-reactive protein, and improves endothelial vasodilator function. These effects do not appear to be closely related, suggesting that pioglitazone may have beneficial vascular properties independent of its effect on insulin sensitivity and inflammation.Keywords
This publication has 18 references indexed in Scilit:
- Prognostic Value of Systemic Endothelial Dysfunction in Patients With Acute Coronary SyndromesCirculation, 2004
- ThiazolidinedionesNew England Journal of Medicine, 2004
- Peroxisome Proliferator-Activated Receptors and AtherogenesisCirculation Research, 2004
- In Type 2 Diabetes, Rosiglitazone Therapy for Insulin Resistance Ameliorates Endothelial Dysfunction Independent of Glucose ControlDiabetes Care, 2004
- Definition of Metabolic SyndromeCirculation, 2004
- Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profileAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- Prognostic Value of Coronary Vascular Endothelial DysfunctionCirculation, 2002
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)Journal of Biological Chemistry, 1995
- Regulatory Functions of the Vascular EndotheliumNew England Journal of Medicine, 1990